All posts by imreal

DuPont Electronics & Imaging Interconnect Solutions Introduces New Metallization Offerings for High-Density Interconnect Applications in Printed Circuit Boards


News Image

“DuPont Electronics & Imaging ICS is committed to delivering a broad platform of integrated and advanced circuit materials to serve the PCB industry, and metallization products are part of it,” said Avi Avula, Vice President, General Manager, DuPont Electronics & Imaging.

DuPont Electronics & Imaging Interconnect Solutions (ICS), the leading integrated materials solution partner for advanced interconnects, today introduced new metallization offerings in advanced development stages for High-Density Interconnect (HDI) applications, a high-performance and fast-growing segment of the printed circuit board (PCB) industry. The offerings are part of the DuPont Electronics & Imaging ICS broad platform of products, where performance is optimized through product synergies and close partnership with customers.

The offerings include newly developed ionic palladium catalyst products for horizontal electroless copper systems, and a next generation via-fill electrolytic copper solution. These next-generation technologies are designed for fine-line HDI applications and deliver both high reliability and improved productivity. These qualities make them particularly suited to various application needs for smartphones, consumer electronics, telecom, and automotive.

“DuPont Electronics & Imaging ICS is committed to delivering a broad platform of integrated and advanced circuit materials to serve the PCB industry, and metallization products are part of it,” said Avi Avula, Vice President, General Manager, DuPont Electronics & Imaging. “We continue to invest in technology to bring new and advanced solutions to our customers, OEMs, and industry partners to drive innovation and enable next-generation product platforms that address the most challenging issues in the industry.”

DuPont Electronics & Imaging ICS metallization products have a long-standing reputation for excellent performance, consistent quality, and support from a strong, global R&D and technical service team with deep fundamental knowledge and know-how. Building upon these strengths, we are launching products in two areas:


  • CIRCUPOSIT™ 6000 series – to address growing demand for ionic catalysts for horizontal electroless copper system. These products deliver high reliability and productivity regardless of application needs.    
  • MICROFILL™ EVF-III – electroplating solution for via-filling and through-hole plating in the fine-line HDI market, providing better surface uniformity, reduced scratch mark sensitivity, and wider operation latitude for a 20% productivity improvement at up to 20 ASF (Amperes per Square Foot).

Both product lines are currently available.

Photo can be downloaded at link: hi-resolution, low-resolution

Caption: DuPont Electronics & Imaging ICS introduced new metallization offerings in advanced development stages for High Density Interconnect (HDI) applications, a high performance and fast-growing segment of the printed circuit board (PCB) industry.

About DuPont Electronics & Imaging

DuPont Electronics & Imaging is a global supplier of materials and technologies serving the semiconductor, advanced chip packaging, circuit board, electronic and industrial finishing, display, and digital and flexographic printing industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies. More information about DuPont Electronics & Imaging can be found on our electronic solutions and image solutions websites.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/.

# # #

5/12/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Winnie Chou

+886-3-3773578

winnie.chou@dupont.com

Share article on social media or email:

Renowned Refractive Surgeon Jeffrey B. Robin, M.D. joins Orlando’s Magruder Laser Vision


Dr. Jeffrey B. Robin

Dr. Jeffrey B. Robin

“… one of the most successful and experienced refractive surgeons in the world,”

Magruder Laser Vision proudly announces that Dr. Jeffrey B. Robin has joined the medical staff as of April 1, 2020. Dr. Robin is a Board-Certified ophthalmologist who has dedicated his career to refractive vision-correction surgery. A graduate of Jefferson Medical College in Philadelphia, he completed his Ophthalmology Residency at Georgetown University. He then completed dual Cornea and Refractive Surgery Fellowships at USC in Los Angeles and LSU in New Orleans. Dr. Robin has held full-time academic positions in the Departments of Ophthalmology at USC, the University of Illinois, and the Cleveland Clinic, as well as part-time positions at Rush Presbyterian and Case Western Reserve. He has been an Associate Professor of Ophthalmology at our own UCF College of Medicine for more than a decade. Dr. Robin has served as President of the International Society of Refractive Surgery and as a member of the Executive Committee of the Refractive Surgery Alliance.

Dr. Robin has performed tens of thousands of refractive surgical procedures. With the addition of Dr. Robin, the combined experience of the Magruder Laser Vision (MLV) surgeons and staff is now well over 100,000 vision correcting procedures. Dr. Robin will be based at Central Florida’s first ophthalmological office-based surgical center, which MLV is opening this summer. With this new center, patients will have access to in-office procedures, including Custom Laser Cataract Surgery, that previously had to be performed off-site.

“We are thrilled to have Dr. Robin on our team,” said Dr. Brock Magruder, Jr, the CEO of MLV. “He is not only one of the most successful and experienced refractive surgeons in the world, he also has a warm and caring manner appreciated by patients and staff alike.”

Dr. Robin will be performing LASIK, PRK or Advanced Surface Ablation, SMILE, INTACS, and corneal inlays. Additionally, he will be spearheading a Dry Eye service at Magruder Laser Vision. When asked about joining MLV, Dr. Robin commented, “I am eager to use my experience to augment the great practice that Doctors Magruder and Shumski have already established and to serve MLV’s patients.”

Magruder Laser Vision is a World Class Boutique Refractive Surgery Center with offices in Downtown and South Orlando. In addition to the corneal procedures listed above, MLV specializes in Custom Laser Cataract Surgery, Custom Lens Exchange, and Intraocular Contact Lenses.

Share article on social media or email:

MUSE Healthcare launches predictive hospice tool with Homecare Homebase


“When we can empower exceptional care during a patient’s final days and help our customers better manage their resources, it’s a win/win for everyone.”

Homecare Homebase℠ (HCHB), the nation’s #1 software for home health and hospice, has partnered with MUSE Healthcare of St. Paul to offer enhanced hospice care during the most critical times of a patient’s care journey. The new product uses sophisticated modeling and machine learning to better predict, prepare and provide for hospice patients in the last 7-12 days of life.

The fast-growing, complex and sensitive hospice service area offers unique challenges for providers seeking to allocate resources when and where they’re needed most. The MUSE solution is designed to address a well-documented gap in end of life care and ensure that every patient transitions with exceptional dignity, comfort and attention.

Tom Maxwell, Co-Founder of MUSE Healthcare said the data science company’s extraordinary insight comes from a vast, ever-growing patient data pool that can accurately predict outcomes based on the most subtle, yet wide-ranging metrics. “We know that the average late-stage patient is often underserved. Our whole goal is to arm hospice staff with information and enable them to offer more caring hospice visits to patients and families in the last 7-12 days of life, with a greater sense of satisfaction for everyone.”

According to Homecare Homebase Chief Strategy Officer Scott Pattillo, patient and family satisfaction is essential in building stronger referrals and long-term business success. “The MUSE product is the perfect fit for our HCHB Business Connect Suite of interoperability products and adds incredible value to our robust hospice solution through its integration. When we can empower exceptional care during a patient’s final days and help our customers better manage their resources, it’s a win/win for everyone.”

About MUSE Healthcare

Muse Healthcare was founded in 2019 by three leading hospice industry professionals — Jennifer Maxwell, Tom Maxwell and Bryan Mosher. Their mission is to equip clinicians with world-class analytics to ensure every hospice patient transitions with unparalleled quality and dignity. Muse’s predictive model considers hundreds of thousands of data points from millions of visits to identify which hospice patients are most likely to transition within 7-12 days. The science that powers Muse is considered a true deep learning neural network – the only one of its kind in the hospice space. When hospice care providers can more accurately predict when their patients will transition, they can ensure their patients and their patients’ families receive the care that matters most in the final days and final hours of a patient’s life.

For more information, visit musehc.com.

About Homecare Homebase, LLC

Homecare Homebase (HCHB) is a Dallas-based software leader offering hosted, cloud-based solutions to streamline operations, simplify compliance and boost clinical and financial outcomes for homecare and hospice agencies. Our customized mobile solutions enable real-time, wireless data exchange and communication between field clinicians, physicians and office staff for better care, more accurate reporting and faster payment. Founded by industry veterans in 1999, the company is now part of the Hearst Health Network. For more information visit hchb.com or call us toll-free at 1-866-535-HCHB (4242).

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 77 million home health visits and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures (http://www.hearsthealth.com). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth or LinkedIn @Hearst-Health.

Share article on social media or email:

Experiential Marketing Heavyweights Join Chicago-Based AKA


AKA Logo

There is no substitute for the real-life experience these two bring to the table – making this partnership a key differentiator for AKA going forward.

Jason Vargas and Scott Moller have joined Chicago-based strategic communications company, AKA. As CMO, Vargas will continue to expand the company’s capabilities to solve marketing communications challenges for clients with brand awareness and brand experience campaigns. Moller will act as Principal, providing senior-level counsel for the company’s roster of blue-chip clients.

“This is both a challenging and exciting time for our clients as they navigate contemporary communications challenges for their brands, their products, their employees and their stakeholders,” said Andrew Krause, Founder and CEO of AKA.

The addition of Scott and Jason allows AKA to offer more impactful solutions to its clients. For example, the agency can now engage customers with memorable experiences, capture those moments on video, create and edit the activity into a compelling story, and deliver it via paid and earned media to achieve results for clients.

Krause acknowledges, “There is no substitute for the real-life experience these two bring to the table – making this partnership a key differentiator for AKA going forward.”

AKA’s tailored approach to projects and scopes works to uncover the root cause of specific challenges. The agency begins by falling in love with the problem in order to identify the correct solution. Effective campaigns must be designed to solve the issue, not merely consist of clever tactics.

“We learned at Marketing Werks that most businesses experience some type of communications challenge,” said Moller. “The solution to those challenges usually involves getting the attention of the ‘right’ people and persuading those people to do the ‘right’ thing. How you do that effectively is where experience matters.”

As co-founder and co-CEO of Marketing Werks, Moller grew the company to become the largest privately-owned experiential marketing agency in the US. His dynamic leadership inspired top talent and attracted well-known brands including PlayStation, Walgreens, Char-Broil, Chase, UnitedHealth Group, IndyCar, Bridgestone and Sony. With over $100 million in annual revenue, Marketing Werks was sold to Dallas-based Crossmark in 2013.

Vargas helped pioneer experiential marketing tied to brand-driven experiences at Marketing Werks, leading award-winning teams for clients including Verizon, Discover and LEGO. Prior to joining Marketing Werks, Vargas worked for GMR Marketing and later served for eight years as Adjunct Professor of Experiential Marketing at The University of Chicago.

Krause founded AKA in 1998 producing and distributing earned media campaigns with celebrities, athletes and CEOs. He’s assembled teams of creatives, content producers, social and media relations experts and digital campaign managers recognized for results-driven, best-in-class service across brand and corporate communications. The boutique shop executes end-to-end project work for companies and brands including Mondelēz, PepsiCo/Gatorade, Kraft/Oscar Mayer, Kraft/Planters, Ace Hardware and McDonald’s.

About AKA

AKA is an award-winning strategic communications company recognized worldwide for solving marketing and communications challenges across brand and corporate communications and agency support categories. Learn more at http://www.akapartners.co.

Follow AKA on LinkedIn at http://www.linkedin.com/company/AKApartnersllc and on all other social handles at @AKApartnersllc.

Share article on social media or email:

Outbrain Responds to the United Nation’s Open Brief to #FlattentheCurve


“We are living in unprecedented and trying times. Our goal, as part of this collective, is to help promote education and awareness globally by using our significant reach to help these messages get critical exposure,” said Yaron Galai, CEO and Co-Founder of Outbrain.

Outbrain, the world’s leading discovery and native advertising platform on the open web, announced today it is part of the collective who have responded to the United Nation’s open brief to help stop the spread of COVID-19. Outbrain is committed to supporting this initiative by distributing approved creatives through its publisher network in the coming weeks.

“We are living in unprecedented and trying times. Our goal, as part of this collective, is to help promote education and awareness globally by using our significant reach to help these messages get critical exposure,” said Yaron Galai, CEO and Co-Founder of Outbrain. “As part of this global pandemic, we have a responsibility to the open web news organizations, to our partners, and to news consumers around the world, to do everything we can to assist.”

With the continuation of the campaign, Outbrain is on track to deliver over half a billion impressions, with users engaging with the ads and clicking through to learn more.

Dawda Jobarteh, Global Head of UN SDG Strategy Hub states, “We have been overwhelmed by the tremendous response from creators around the globe who have leaned in to help humanity in the face of this unprecedented crisis. This pandemic demands collective action and global collaboration. The creative community has delivered powerful messages that transcend borders, languages, cultures, and mediums, to help reach everyone in this fight against COVID-19. That fight begins with personal behavior change and a clear understanding of the facts, so communications couldn’t be more important. Now, the challenge is to get these inspiring works seen and heard by people all over the world, especially where the need is greatest. We are thrilled to have the support of Outbrain in helping to realize that.”

The United Nations has requested support from creatives and media owners to promote key COVID19 messaging to people around the world. To find out more, visit United Nations Global Call Out To Creatives.

Share article on social media or email:

DrOwl’s Medical Tech Platform Allows Medicare and Medicaid Patients Access to their Medical Records in a New Way


News Image

It is my firm belief that the more involved the patient, their family, and caregivers, the better the outcome for the patient. We built DrOwl as a simple-to-use technology to increase the patient’s engagement in their own healthcare.

DrOwl, a medical technology platform built on patented technology, announced today the launch of a new platform designed to allow Medicare and Medicaid patients to access, organize, search, and share their digital medical records on demand.

Most people have medical records in numerous hospitals, doctors’ offices, and health clinics. These “traditional”, compartmentalized medical record systems, silo the information away from the patient. Gaining access to these records is often difficult, and sharing information was challenging, until now.

The HIPAA-compliant DrOwl platform is offering a free tool for CMS (Medicare/Medicaid) patients to help understand their medical records. Every CMS (Medicare/Medicaid) Patient can sign in to DrOwl for free and bring in their medical records. DrOwl combines the patient’s medical record data, with proprietary AI and machine learning, to create a unique Patient Snapshot, as well as a Patient Portal which is in easy-to-understand language personalized to each patient’s medical conditions. A Personal Health Search Engine is also created for the patient to search the information in their patient portal that is unique to them. Medicare/Medicaid patients can easily read and research their medical conditions and medications in a physician-approved, trusted environment.

Patients can easily share their DrOwl patient portal with doctors, caregivers, or family members. Family members can help participate in the care of their loved ones and understand their conditions and medications in a new way.

“Being a caregiver for my mom for many years, I have a deep understanding of the challenges that patients and their caregivers face every day when it comes to accessing and understanding medical records and health conditions. DrOwl was created to give people control over their medical records and an easy way to help them understand their conditions,” said Arvind Raichur, CEO, and Co-Founder of DrOwl.

DrOwl is also rolling out telemedicine services in select areas. But the DrOwl Telemedicine platform is different from what has traditionally existed in telemedicine platforms. Patients can “chat in-app” with medical providers or participate in a video call with a physician with the click of a button, in real-time. The DrOwl telemedicine providers have access to the patient’s medical records on DrOwl including the Patient Snapshot, Patient Portal, and Personal Health Search Engine. This access to the medical records of the patients allows the DrOwl Telemedicine providers a clear snapshot of the patient’s medical history. This can lead to more efficient medical care.

Users of DrOwl can involve their loved ones in their care in a new way. Patients can add caregivers or family members to their telemedicine visits, as needed, so that the people who help to take care of them can be a part of important medical conversations, regardless of their location or time zone.

DrOwl users will have ongoing access to 100’s of physicians, including infectious disease specialists, hospitalists, generalists, and nurses, beginning with areas in Florida, with other locations coming online very shortly.

The platform also syncs with known wearable health technologies (e.g. Fitbit, Apple Health, etc.) and updates the Patient Portal for things like heart rate, steps, and more. This helps add valuable information to the patient’s medical history.

Dr. Krishan Nagda, MD, the President of DrOwl, said, “It is my firm belief that the more involved the patient, their family, and caregivers, the better the outcome for the patient. We built DrOwl as a simple-to-use technology to increase the patient’s engagement in their own healthcare. When patients are informed and educated about their health, they have the power to make more informed decisions.”

The technology also includes a tool for users to understand their risk factors for COVID-19. Users can see if they are in a group that needs to take extra precautions during outbreaks of infectious diseases.

To find out more, go to DrOwl.com or download it for free from the iTunes or Google Play app stores.

About DrOwl

DrOwl is a medical platform built on patented technology, that provides a safe place to store your medical records. It was built to store, organize, search, and share your digital medical records on demand.

Once a user securely stores their medical records, DrOwl uses AI and machine learning to provide users with a Patient Portal based on the Patient’s health records that include trusted, doctor-approved sources of information that is customized for each user and makes their medical information easier to understand. DrOwl users can also share their customized Patient Portal with caregivers or family members to include them in the patient’s healthcare decisions. Users can initiate telehealth sessions and allow their caregivers or family members to join in the secure telemedicine video call.

DrOwl provides a free electronic screening solution to help protect businesses. DrOwl’s free screening tools allows businesses to screen their employees, vendors, and visitors in order to keep their workforces and facilities as safe as possible during a difficult period.

Share article on social media or email:

Cecelia Health Providing Critical Telehealth Support to Diabetes Specialty Clinics in Partnership with the Helmsley Charitable Trust


Cecelia Health

Right now, we need to make sure that anyone who can’t get to their doctor can still get support, and we know Cecelia can fill that gap.

Cecelia Health is providing essential clinical support to people of all ages living with Type 1 and Type 2 diabetes around the country in response to challenges resulting from the COVID-19 pandemic. In partnership with the Helmsley Charitable Trust, Cecelia Health’s virtual care is an invaluable alternative to in-person visits with endocrinologists and other clinical staff for actively and successfully managing diabetes.

“Cecelia Health has an army of Certified Diabetes Care and Education Specialists (CDCESs) providing remote telehealth support to both adults and children living with insulin-dependent diabetes. Right now, we need to make sure that anyone who can’t get to their doctor can still get support, and we know Cecelia can fill that gap,” said David Panzirer, Trustee of the Helmsley Charitable Trust.

Nationwide, over 50 universities and hospitals are receiving funding from Helmsley for their diabetes clinics to help them through the COVID-19 crisis. In addition to financial support, a subset of these clinics will have access to Cecelia Health’s CDCESs to assist both patients and clinicians with providing a spectrum of support to people in managing their insulin-dependent diabetes to ease the daily burden and help improve outcomes, including:


  • Increasing success with using technologies like continuous glucose monitors (CGM) or blood glucose meters (BGM), or insulin pumps,
  • Helping people with diabetes prepare for scheduled telemedicine visits, including uploading their CGM and insulin data to allow easy review by clinic staff,
  • Providing support and education to children and parents and caregivers of children living with Type 1 diabetes,
  • Assessing possible dosage and titration changes and facilitating follow up with endocrinologists if needed,
  • Support for making small yet significant behavior or lifestyle changes, and
  • Lending an ear at a moment when mental health is on the line for everyone, and especially for people living with increased risk of COVID-19 due to their diabetes.

“Cecelia Health’s CDCESs augment our team’s efforts to reach out to our patients, provide training and education, and prepare them for telemedicine visits. This is a tremendous help as we try to work with as many patients as possible during our rapid transition to telemedicine necessitated by COVID-19, said Dr. Ruth Weinstock, Founder and Medical Director of the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse.” Cecelia Health’s CDCES team is providing personalized and compassionate care to our patients, and we are all grateful for the added bandwidth during this challenging time.”

CDCESs will also help educate patients on resources for discounted or free medication and diabetes supplies and facilitate prior authorizations and letters of medical necessity.

“The COVID-19 pandemic has created additional complexity for people with diabetes on top of their everyday challenges they face. As an example, patients who rely on access to their providers and clinical teams for their medications, care, education and diabetes management now are not able to get those vital services. In partnership with the Helmsley Charitable Trust, we are grateful to provide our services to people living with diabetes during this difficult time” said Cecelia Health CEO and Founder, David Weingard.

About Cecelia Health

Cecelia Health’s mission is to transform and improve the lives of people living with chronic conditions worldwide. Cecelia Health has a proven track record of driving improved clinical outcomes and return on investment for customers. The Cecelia Health clinical team is comprised of nurses, dietitians, exercise physiologists, pharmacists, and social workers who are passionate about empowering people with chronic conditions to live rich, healthy and fulfilling lives. Cecelia Health partners with ACOs seeking to improve quality measures, and pharmaceutical and medical device companies seeking to improve adherence. Cecelia Health has also engaged in numerous joint initiatives with the JDRF, American Diabetes Association, the Diabetes Research Institute, the Association of Diabetes Care & Education Specialists, and The Helmsley Charitable Trust. Through their dedicated COVID-19 Resource Center. Cecelia Health is providing the latest information on how to best cope with this pandemic outbreak.

Share article on social media or email:

NASH Clinical Development During the COVID-19 (Coronavirus) Pandemic, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Trials that are targeting a Q3 or Q4 2020 start could accelerate the start-up period by activating all sites prior to First Person In (FPI), enabling a large proportion to start screening and enrolling simultaneously once the hold is lifted.

The COVID-19 pandemic has brought unprecedented challenges in clinical development. Travel restrictions, social distancing and the fear of contracting the disease are impeding conventional trial conduct. Typically, routine patient and monitoring visits to healthcare facilities are now the exception, study coordinators and site staff have increased demands on their time and, in some cases, layoffs have rendered some sites incapable of continuing as usual. To help keep patients safe and allow trials to progress, regulatory authorities worldwide have issued guidance for industry, investigators and institutional review boards. Exceptional measures are rapidly being put in place in different countries. As a consequence, we have witnessed a range of responses from sponsors on clinical trial activity, such as delaying trial starts, halting screening/enrollment in most ongoing studies and changing Investigational Medicinal Product (IMP) distribution and site visits.

Our ability to adapt our approach in this ever-changing environment is critical and as a company Covance is at the forefront of partnering with specific vendors who are able to assist us in virtual technologies. These technologies enable virtual patient visits through telemedicine and phone interviews, shipping, storage and self-administration of IMP at patients’ homes and remote CRA monitoring visits. Trials that are targeting a Q3 or Q4 2020 start could accelerate the start-up period by activating all sites prior to First Person In (FPI), enabling a large proportion to start screening and enrolling simultaneously once the hold is lifted. These suggestions could help trials move forward in the face of quarantine and travel limitations, clinical site closures and altered supply chains.

Join our panel of experts from Covance along with Naim Alkhouri, MD, Director, Texas Metabolic Center and Texas Liver Institute Hepatologist for an informative live discussion on Thursday, May 28, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit NASH Clinical Development During the COVID-19 (Coronavirus) Pandemic.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

SPH Analytics’ Receives Client Satisfaction Award, Expands Leadership Team


SPH Analytics received the 2020 Highest Client Satisfaction award for Population Health vendors for the fourth year in a row.

SPH Analytics received the 2020 Highest Client Satisfaction award for Population Health vendors for the fourth year in a row.

SPH Analytics, a leader in healthcare quality and experience analytics, recently received the 2020 Highest Client Satisfaction award for its population health business unit from industry analyst Black Book Research. This is the fourth consecutive year that SPH Analytics received the top Population Health client satisfaction award for End-to-End Population Health Analytics Vendors, as determined by a random sample of U.S.-based healthcare organizations.

To add further momentum to its Population Health and Value Based Care efforts, SPH Analytics also announced it expanded its leadership team, adding industry veteran Kevin Weinstein as President, Population Health. Weinstein spent the last twenty years working with growth stage healthcare companies, primarily focused on technology and services supporting providers and payers. His previous experience includes leadership roles at Allscripts, ZirMed, Rise Health, Valence Health, Analyte Health, and Apervita.

“We are pleased to welcome Kevin to our Executive Leadership Team to provide focused leadership for our population health division. Our growth, innovation agenda and expanding base of clients that we serve warrants incremental executive focus on this important division of our business. Kevin joins SPH at a place in our journey where we have earned sustained, exceptional client satisfaction, and his deep industry knowledge and innovative mindset will be critical to our ability to continue to drive even greater value that we bring to our clients, ” said Amy Amick, CEO of SPH Analytics.

Amick continued, “This latest award serves as recognition of SPH Analytics’ relentless focus on our clients to help drive improved outcomes and lower costs. The most important aspiration we have for ourselves is to create great value for our clients; to be recognized year after year only further validates that we are delivering real impact and value for the providers and payers that we serve.”

“I am thrilled to join SPH’s award-winning team. SPH is a recognized leader in supporting the industry’s transition to value-based care and has proven themselves as an exceptional partner to both providers and payers as they manage the health of their respective populations,” said Weinstein. “I look forward to helping SPH continue to grow and help support the health of more than 40 million Americans.”

About Black Book Research

Black Book Research issues annual client experience, brand loyalty, and satisfaction rankings for a variety of technology and managed services fields, including ambulatory/ physician Electronic health record (EHR), Health Information Exchanges (HIE), banking, insurance, education, outsourcing and government. Black Book produces over two hundred annual market research reports focused on the healthcare technology solutions and services industry, under the names Black Book Research and Black Book Rankings.

About SPH Analytics

SPH Analytics (SPH), a leader in healthcare analytics and population health management, empowers clients to analyze and interpret their clinical, financial, and consumer experience data to maximize their performance. SPH’s Population Care™, Population Value™, and Population Engage™ solutions are built on the innovative Nexus™ Platform, providing insights and impact to integrated health networks, ACOs, hospitals, ambulatory care providers, physician groups, and health plans. SPH’s quality measure dashboards, financial risk measurement, healthcare survey and patient outreach solutions, and consulting services empower clients to meet the Triple Aim by improving population health, reducing overall cost of care, and improving the patient experience.

SPH Analytics is headquartered in metro Atlanta and has provided insights to clients for more than 35 years, serving clients in all 50 states. For more information, call 1-866-460-5681 or visit SPHAnalytics.com.

Share article on social media or email:

Singota Solutions Collaborates with Noveome Biotherapeutics, Inc. to Manufacture Promising Therapy to Treat Severe Condition in People Infected with COVID-19


News Image

Singota is proud to work with Noveome in the fight against the coronavirus, especially to help the patients around the world, but also those close to home.

Singota Solutions has been selected to collaborate with Noveome Biotherapeutics, Inc. to manufacture the ST266 investigational drug product, a biologic being evaluated in clinical studies for its potential treatment of the severe inflammatory reaction known as Cytokine Release Syndrome (CRS), also known as the Cytokine Storm, observed in COVID-19 patients.

Singota specializes in small batch aseptic filling of high-value injectable products into vial, syringe, and cartridge formats using the robotic Vanrx SA25 Aseptic Filling Workcell. Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials. In preclinical and clinical studies, ST266 has demonstrated significant anti-inflammatory activity, which could potentially be lifesaving for patients experiencing the often-fatal CRS, a severe and systemic complication of COVID-19 that causes multi-organ damage, especially to the lungs.

“We commit to working quickly, yet carefully to get our clients’ products out to patients,” said Laura Englander, Senior Business Development and Marketing Manager. “Noveome has been a great partner for Singota. They have moved swiftly on the front-end, entrusting us to excel at our promise of adhering to their tight timeline to get this critical product ready for their patients.”

Singota will manufacture 30 mL vial fills of ST266 in June. This timeline helps Noveome in its accelerated efforts to treat patients in the clinic, which they are prepared to initiate immediately should the FDA approve its requested authorization to proceed with dosing.

In response to the collaboration, Alisa Kilgas, CEO at Singota stated, “We’re all in this together. Singota is proud to work with Noveome in the fight against the coronavirus, especially to help the patients around the world, but also those close to home.”

“Noveome is aggressively pursuing our investigational drug ST266 as an important therapeutic in the treatment of patients experiencing one of the most serious and life-threatening conditions brought about by COVID-19 infection. Singota’s application of isolators paired with single-use technologies uniquely positions them to establish GMP manufacturing in weeks as opposed to what would typically take several months. In addition to this enabling technology, the response and flexibility of the team at Singota has been exceptional in the rapid establishment of this collaboration,” said Kevin McCracken, Chief Operating Officer, Noveome Biotherapeutics, Inc.

For more information about our services, please contact Laura Englander at laura.englander@singota.com or (812) 961-1752.

About Singota Solutions

Singota Solutions is a contract development and manufacturing organization focused on moving products through the development pipeline faster—with agility, accountability, and transparency. Founded in 2006, the company is a woman-owned business operating in Bloomington, Indiana. Singota’s gloveless, robotic aseptic filling service is ideally suited for the production of clinical and niche commercial injectable products in vial, syringe, and cartridges formats. Singota also provides customized solutions for formulation development, supply chain & materials management, analytical testing, and labeling and kitting services. For more information, please visit http://www.singota.com.

About Noveome® Biotherapeutics

Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has launched a program to test its novel platform biologic, ST266, as a treatment for the severe inflammatory response seen in COVID-19 infection. ST266 is currently being evaluated in multiple indications including a Phase 1 open-label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose to brain and eye and a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing persistent corneal epithelial defects (PEDs). For more information, visit http://www.noveome.com.

Share article on social media or email: